Madison Darmofal

Madison Darmofal

Auto-generated profile, based on publicly available information

Madison Darmofal

Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell
Verified
Journal Article
Closed access
KHKevin Hadi
Kevin Hadi
XYXiaotong Yao
Xiaotong Yao
JBJulie M. Behr
Julie M. Behr
ADAditya Deshpande
Aditya Deshpande
CXCharalampos Xanthopoulakis
Charalampos Xanthopoulakis
MIMarcin Imielinski
Marcin Imielinski

27 February 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MDMadison Darmofal
Madison Darmofal
SSShalabh Suman
Shalabh Suman
GAGurnit Atwal
Gurnit Atwal
MTMichael Toomey
Michael Toomey
JCJie-Fu Chen
Jie-Fu Chen
QMQuaid Morris
Quaid Morris
Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor-type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole-genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a data set of 39,787 solid tumors sequenced using a clinically targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks. GDD-ENS achieves 93% accuracy for high-confidence predictions across 38 cancer types, rivaling the performance of WGS-based methods. GDD-ENS can also guide diagnoses of rare type and cancers of unknown primary and incorporate patient-specific clinical information for improved predictions. Overall, integrating GDD-ENS into prospective clinical sequencing workflows could provide clinically relevant tumor-type predictions to guide treatment decisions in real time. Significance: We describe a highly accurate tumor-type prediction model, designed specifically for clinical implementation. Our model relies only on widely used cancer gene panel sequencing data, predicts across 38 distinct cancer types, and supports integration of patient-specific nongenomic information for enhanced decision support in challenging diagnostic situations. See related commentary by Garg, p. 906. This article is featured in Selected Articles from This Issue, p. 897

3 June 2024
Verified
Other
Open access
MDMadison Darmofal
Madison Darmofal
SSShalabh Suman
Shalabh Suman
GAGurnit Atwal
Gurnit Atwal
MTMichael Toomey
Michael Toomey
JCJie-Fu Chen
Jie-Fu Chen
QMQuaid Morris
Quaid Morris
Top Shapley values per organ system. Shapnorm = shapley effect score normalized across all predictions of the cancer type

3 June 2024
Verified
Other
Open access
MDMadison Darmofal
Madison Darmofal
SSShalabh Suman
Shalabh Suman
GAGurnit Atwal
Gurnit Atwal
MTMichael Toomey
Michael Toomey
JCJie-Fu Chen
Jie-Fu Chen
QMQuaid Morris
Quaid Morris
Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor-type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole-genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a data set of 39,787 solid tumors sequenced using a clinically targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks. GDD-ENS achieves 93% accuracy for high-confidence predictions across 38 cancer types, rivaling the performance of WGS-based methods. GDD-ENS can also guide diagnoses of rare type and cancers of unknown primary and incorporate patient-specific clinical information for improved predictions. Overall, integrating GDD-ENS into prospective clinical sequencing workflows could provide clinically relevant tumor-type predictions to guide treatment decisions in real time.Significance:We describe a highly accurate tumor-type prediction model, designed specifically for clinical implementation. Our model relies only on widely used cancer gene panel sequencing data, predicts across 38 distinct cancer types, and supports integration of patient-specific nongenomic information for enhanced decision support in challenging diagnostic situations.See related commentary by Garg, p. 906.This article is featured in Selected Articles from This Issue, p. 897

12 June 2024
Verified
Other
Open access
MDMadison Darmofal
Madison Darmofal
SSShalabh Suman
Shalabh Suman
GAGurnit Atwal
Gurnit Atwal
MTMichael Toomey
Michael Toomey
JCJie-Fu Chen
Jie-Fu Chen
QMQuaid Morris
Quaid Morris
Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor-type classifiers trained on genomic features have been explored, but the most accurate methods are not clinically feasible, relying on features derived from whole-genome sequencing (WGS), or predicting across limited cancer types. We use genomic features from a data set of 39,787 solid tumors sequenced using a clinically targeted cancer gene panel to develop Genome-Derived-Diagnosis Ensemble (GDD-ENS): a hyperparameter ensemble for classifying tumor type using deep neural networks. GDD-ENS achieves 93% accuracy for high-confidence predictions across 38 cancer types, rivaling the performance of WGS-based methods. GDD-ENS can also guide diagnoses of rare type and cancers of unknown primary and incorporate patient-specific clinical information for improved predictions. Overall, integrating GDD-ENS into prospective clinical sequencing workflows could provide clinically relevant tumor-type predictions to guide treatment decisions in real time.Significance:We describe a highly accurate tumor-type prediction model, designed specifically for clinical implementation. Our model relies only on widely used cancer gene panel sequencing data, predicts across 38 distinct cancer types, and supports integration of patient-specific nongenomic information for enhanced decision support in challenging diagnostic situations.See related commentary by Garg, p. 906.This article is featured in Selected Articles from This Issue, p. 897

12 June 2024
Verified
Other
Open access
MDMadison Darmofal
Madison Darmofal
SSShalabh Suman
Shalabh Suman
GAGurnit Atwal
Gurnit Atwal
MTMichael Toomey
Michael Toomey
JCJie-Fu Chen
Jie-Fu Chen
QMQuaid Morris
Quaid Morris
All Sample IDs and associated AACR-GENIE IDs, Cancer Types and classification category (train, test, CUP etc)